Flip the cards to learn more about antifibrotic therapies and why mechanisms matter
Targets myofibroblast activity & profibrotic pathways (incl. TGF-β)📊 Phase 3 (n=1,177): 9 & 18 mg BID slowed FVC decline at 52 wks vs placebo ▪ strongest effect without background antifibrotics
Title
Use this side to give more information about a topic.
🟦 Nerandomilast (PDE4B inhibitor)
Subtitle
Modulates TGF-β–driven fibrosis 📊 ~48% relative reduction in significant FVC decline or death
Title
Use this side to give more information about a topic.
🟧 Pirfenidone
Subtitle
Blocks VEGF/FGF/PDGF signalling📊 ~50% reduction in annual FVC decline
Title
Use this side to give more information about a topic.
🟩 Nintedanib
Subtitle
Pulmonary Fibrosis Social Series Flash Cards - Post 6 - Mobile
Phil McElnay
Created on January 27, 2026
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Decisions and Behaviors in the Workplace
View
Tangram Game
View
Process Flow: Corporate Recruitment
View
Weekly Corporate Challenge
View
Wellbeing and Healthy Routines
View
Match the Verbs in Spanish: Present and Past
View
Planets Sorting Game
Explore all templates
Transcript
Flip the cards to learn more about antifibrotic therapies and why mechanisms matter
Targets myofibroblast activity & profibrotic pathways (incl. TGF-β)📊 Phase 3 (n=1,177): 9 & 18 mg BID slowed FVC decline at 52 wks vs placebo ▪ strongest effect without background antifibrotics
Title
Use this side to give more information about a topic.
🟦 Nerandomilast (PDE4B inhibitor)
Subtitle
Modulates TGF-β–driven fibrosis 📊 ~48% relative reduction in significant FVC decline or death
Title
Use this side to give more information about a topic.
🟧 Pirfenidone
Subtitle
Blocks VEGF/FGF/PDGF signalling📊 ~50% reduction in annual FVC decline
Title
Use this side to give more information about a topic.
🟩 Nintedanib
Subtitle